Severe Hypertriglyceridemia

12
Pipeline Programs
4
Companies
11
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
7
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
3100%
+ 8 programs with unclassified modality

On Market (1)

Approved therapies currently available

Arrowhead Pharmaceuticals
REDEMPLOApproved
plozasiran
Arrowhead Pharmaceuticals
APOC-III-directed RNA Interaction [EPC]subcutaneous2025

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Arrowhead Pharmaceuticals
4 programs
1
3
1
PlozasiranPhase 31 trial
Plozasiran InjectionPhase 31 trial
Plozasiran InjectionPhase 31 trial
ARO-APOC3Phase 21 trial
Active Trials
NCT04720534Completed229Est. Aug 2023
NCT06880770Recruiting288Est. Jun 2029
NCT06347003Active Not Recruiting446Est. Sep 2026
+1 more trials
Ionis Pharmaceuticals
3 programs
3
OlezarsenPhase 3RNA Therapeutic1 trial
OlezarsenPhase 3RNA Therapeutic1 trial
OlezarsenPhase 3RNA Therapeutic1 trial
Active Trials
NCT05552326Completed446Est. Sep 2025
NCT05681351Active Not Recruiting885Est. Mar 2027
NCT05079919Completed617Est. Jul 2025
89bio
89bioCA - San Francisco
2 programs
1
1
PegozaferminPhase 31 trial
PegozaferminPhase 21 trial
Active Trials
NCT04541186Completed86Est. May 2022
NCT05852431Active Not Recruiting360Est. Apr 2026
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
1
1
EpanovaPhase 21 trial
EpanovaPhase 11 trial
Active Trials
NCT02189252Completed30Est. Jul 2015
NCT01208961Completed54Est. Nov 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Arrowhead PharmaceuticalsPlozasiran
Arrowhead PharmaceuticalsPlozasiran Injection
Arrowhead PharmaceuticalsPlozasiran Injection
89bioPegozafermin
Ionis PharmaceuticalsOlezarsen
Ionis PharmaceuticalsOlezarsen
Ionis PharmaceuticalsOlezarsen
Arrowhead PharmaceuticalsARO-APOC3
89bioPegozafermin
AstraZenecaEpanova
AstraZenecaEpanova

Clinical Trials (11)

Total enrollment: 3,752 patients across 11 trials

NCT06880770Arrowhead PharmaceuticalsPlozasiran

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Start: Apr 2025Est. completion: Jun 2029288 patients
Phase 3Recruiting
NCT06347016Arrowhead PharmaceuticalsPlozasiran Injection

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Start: Jul 2024Est. completion: Sep 2026311 patients
Phase 3Active Not Recruiting
NCT06347003Arrowhead PharmaceuticalsPlozasiran Injection

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Start: Jul 2024Est. completion: Sep 2026446 patients
Phase 3Active Not Recruiting
NCT0585243189bioPegozafermin

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Start: Jun 2023Est. completion: Apr 2026360 patients
Phase 3Active Not Recruiting
NCT05681351Ionis PharmaceuticalsOlezarsen

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Start: Dec 2022Est. completion: Mar 2027885 patients
Phase 3Active Not Recruiting
NCT05552326Ionis PharmaceuticalsOlezarsen

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Start: Aug 2022Est. completion: Sep 2025446 patients
Phase 3Completed
NCT05079919Ionis PharmaceuticalsOlezarsen

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Start: Oct 2021Est. completion: Jul 2025617 patients
Phase 3Completed
NCT04720534Arrowhead PharmaceuticalsARO-APOC3

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Start: May 2021Est. completion: Aug 2023229 patients
Phase 2Completed
NCT0454118689bioPegozafermin

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

Start: Sep 2020Est. completion: May 202286 patients
Phase 2Completed
NCT01208961AstraZenecaEpanova

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

Start: Sep 2010Est. completion: Nov 201054 patients
Phase 2Completed
NCT02189252AstraZenecaEpanova

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

Start: Oct 2014Est. completion: Jul 201530 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 3,752 patients
4 companies competing in this space